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Abstract
There is currently no noninvasive, reliable method of assessing brain tumor malignancy or of
monitoring tumor treatment response. Monitoring changes to tumor vasculature might provide an
effective means of assessing both tumor aggressiveness and treatment efficacy. To date, most such
research has concentrated upon tumor “microvascular” imaging, with permeability and/or perfusion
imaging used to assess vessel changes at the subvoxel level. An alternative approach assesses tumor
vasculature at the “macroscopic” level, calculating the numbers and shapes of the larger vessels
discriminable by magnetic resonance angiography. This paper provides an overview of magnetic
resonance (MR) vascular imaging at both the microscopic (dynamic MR perfusion and permeability)
and macroscopic (MR angiographic) levels. The two approaches provide different, complementary
information and together could provide important insights into cancer growth as well as new methods
of assessing malignancy and tumor treatment response.
1 Introduction
There is clinical need for a reliable, noninvasive method of assessing brain tumor malignancy
and of evaluating treatment response. The American Cancer Society estimates that in 2006
approximately 19,000 new brain tumors will be diagnosed in the US (ACS 2006). Many
thousands of additional patients exhibit abnormalities of unknown significance on screening
magnetic resonance (MR) studies. Malignant disease should usually be treated aggressively,
whereas benign disease is often treated by watchful waiting. There is currently no effective,
clinically accepted, non-invasive method of separating benign from malignant disease.
An even more difficult problem is posed by treatment monitoring. Effective therapy should
usually be continued as long as it remains effective, but once it begins to fail it should be
changed rapidly. The current standard of practice is to estimate tumor volumes from sequential
sets of gadolinium-enhanced, T1 images (Hadley 2005). Such assessments depend upon
comparison of current to past tumor volumes, do not directly evaluate what the tumor will do
next, and are readily confounded by the necrosis that may appear with successful treatment,
since necrosis can induce enhancement and edema indistinguishable from that of tumor growth.
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A reliable method of assessing tumor metabolic or physiologic activity noninvasively would
be of high value. MR-spectroscopy and Positron Emission Tomography are two imaging
methods under investigation by several groups. Another promising approach is to assess tumor-
associated vasculature. The large majority of such research has concentrated upon the
microvasculature. Recently, several papers have proposed analyzing vessel morphology at the
“macroscopic” level, using vessels segmented from magnetic resonance angiograms (MRA).
The purpose of this report is to review MR imaging of tumor-associated vasculature at both
the microscopic and the macroscopic levels.
2 Background Information
Tumor growth beyond minimal size is dependent upon angiogenesis, the process of new blood
vessel formation from existing vessels (Folkman 1971). Vessels are recruited via the expression
of agents such as Vascular Endothelial Growth Factor (VEGF) and other growth factors
(Ferrara 1996, McDonald 2002). Although malignant tumors tend to be more vascular than
benign lesions, some benign tumors may be more vascular than many cancers. Moreover,
different regions of the same tumor may exhibit different levels of vascularization.
Cancer-associated changes to vascular morphology occur very early during tumor growth.
Within 24 hours of injection of only a few 10s of cancer cells, initially healthy vessels in the
tumor vicinity develop tortuosity abnormalities, with such changes emerging prior to
angiogenic sprouting and affecting vessels well beyond the tumor margins (Li 2000).
Tortuosity abnormalities appear across cancer types, and have been aptly described by Baish
as “many smaller bends upon each larger bend” (Baish 2000) [Figure 1]. With time, effects
can spread to even major named vessels, with MR-apparent alterations occurring a centimeter
or more outside of any T1-gadolinium enhancing lesion [Bullitt 2007].
The cause of this vessel morphological change is probably cancer-induced alteration of the
vessel wall. Such alterations include modification of the basement membrane, endothelial cell
fenestrae, reduction of pericytes and smooth muscle, and the formation of blind saccular
extensions (McDonald 2002). This vessel wall disruption also often produces a “leaky vessel”,
in which intravascular contents leak into interstitial tissues. Successful tumor treatment leads
to regression of tumor-associated vascular morphological and permeability alterations (Yuan
1996, Baish 2000, Li 2000, Bullitt 2004 2007, Willett 2004, Jain 2005). The time course is
rapid (hours to days) when anti-angiogenic treatment is administered.
3 Microscopic Imaging: Dynamic Perfusion and Permeability
The goals of dynamic MR perfusion and permeability imaging are to assess regional cerebral
blood flow, volume, and permeability via sequential image acquisitions during contrast
injection. Changes in intensity values are compared over time within a single voxel or cluster
of voxels following injection of contrast. The choice of contrast agent may be gadolinium or
a larger molecule that leaks into the extravascular space under conditions of high permeability
but not otherwise. Figure 2 illustrates a cerebral blood flow map in a patient with a malignant
tumor.
A generic advantage of perfusion and permeability imaging is that they both incorporate
microvascular information. However, a disadvantage is that voxels are large and the data are
noisy. Values may vary across healthy subjects and from time to time in an individual patient.
Furthermore, seizures alter both vascular permeability and blood flow (Leonhardt 2005).
Corticosteroid administration also alters values (Ostergaard 1999). Such effects complicate
tumor evaluation.
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The assumption when evaluating tumors by MR perfusion/permeability is that at least some
regions within higher grade tumors will exhibit higher blood flow and greater permeability
than do lower grade tumors. Results obtained from correlating glioma grade with regional
blood volume/flow do indeed suggest that higher grade tumors tend to display higher blood
flow/volume, but both specificity and sensitivity remain a concern (Aronen 2002, Jackson
2002, Covarrubias 2004). Permeability measurements also suggest that higher grade tumors
tend to exhibit higher permeability. However, similar to the results for perfusion, there is
overlap of values (Roberts 2000, Provenzale 2002, Covarrubias 2004).
When making the distinction between radiation necrosis and tumor growth, one would expect
that an actively growing tumor should possess higher blood flow/volume than a purely necrotic
lesion. Indeed, Sugahara analyzed regional cerebral blood volume in 20 patients, concluding
that a normalized rCBV ratio higher than 2.6 was indicative of malignancy and a value less
than 0.6 of necrosis (Sugahara 2000). Unfortunately, 12 of 20 tumors fell into the indeterminate
range. Better results were reported by Hazle, who used T1 weighted permeability and noted
that necrotic and tumorous regions enhanced at different rates (Hazle 1997).
Anti-tumor agents specifically targeted to combat the effects of VEGF are now becoming
available. The effects of therapy upon the vasculature may be complex, however. After one
week of anti-VEGF therapy in mice with colon cancer, Wieldiers noted both a decrease in
vascular density and an increase in overall perfusion (Wildiers 2006). This increase in
perfusion, despite a diminution in vascular density, may be related to normalization of
tortuosity in the larger feeding vessels (Jain 2005). By contrast, Willett describes both a
decrease in vessel density and a decrease in tumor perfusion and blood volume following anti-
VEGF treatment (Willett 2004), as might be expected following tumor regression.
4 Macroscopic Imaging: Vessel shape analysis from MRA
A different approach to the analysis of tumor associated vasculature is via a quantitative,
statistical measure of vessel shape provided by the vessels segmented from time-of-flight, non-
enhanced MRA. Much less is known about the relative disadvantages and advantages of this
method both because it is relatively new and because work has been done predominantly by
only one group. A disadvantage of this approach is that it inherently cannot analyze vessels of
diameter less than the voxel size used during image acquisition. A second disadvantage is that
image processing time may require an hour. An advantage, however, is that individual vessels
can be followed over time. The fundamental difference between the two approaches is that
microscopic imaging provides information that includes clusters of vessels too small to be
individually discerned by MR (thus including information that macroscopic imaging cannot)
but that macroscopic imaging provides multiple measures of vessel morphology.
Bullitt describes a blinded study in which MRA images of 30 tumor subjects were analyzed
prior to total gross resection of each lesion, with all but one lesion (a false negative) correctly
classified as malignant or benign on the basis of vessel tortuosity (Bullitt 2005). Cases included
those difficult to classify by any current method and included hypervascular benign tumors,
irradiated cancers, radiation necrosis, hemorrhagic lesions, and “pinpoint” lesions. Tiny
cancers occupying only a few voxels on gadolinium enhanced MR could correctly be defined
as malignant on the basis of vessel shape because vessel tortuosity abnormalities affect the
vessels not only within the cancer but in the surrounding neighborhood as well.
An important question is how large a cancer must be before vessel shape abnormalities can be
perceived by MRA. In a study that evaluated mice genetically engineered to develop
carcinoma, cancers larger than 1 mm3 could be correctly classified as malignant on the basis
of vessel tortuosity (Bullitt 2006).
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Normalization of vessel tortuosity as visualized by MRA appears to occur during successful
treatment of human cancer patients (Bullitt 2004, 2007). Figure 3 illustrates vessel shape
normalization in a patient who underwent MRA imaging prior to initiation of treatment and 2
months after beginning a successful course of chemotherapy. Note that the later image
demonstrates not only disappearance of tiny abnormal vessels but also resolution of tortuosity
abnormalities in large vessels. Vessels at the second time point also exhibit normalization of
vessel radii, with enlargement of the initially very narrow, tortuous right frontopolar artery and
reduction in radius of the initially engorged left frontopolar artery. This enlargement of some
vessels with concomitant decrease in radius of others may explain the previous contradictory
reports on the increase/decrease of perfusion levels following tumor treatment (Wildiers
2006, Willett 2004). Insufficient data is available, however, to know if the macroscopic
imaging approach will ultimately prove clinically useful when analyzing tumors of a variety
of types and under various treatment regimens.
5 Discussion
The microscopic and macroscopic imaging methods outlined above have different advantages
and disadvantages. Microscopic vessel analysis has the advantage of including tiny vessels at
subvoxel resolution. However, large and small vessels are considered together, the approach
may be sensitive to acute changes in the environment, and individual vessels cannot be followed
over time. Conversely, macroscopic vessel analysis can follow individual vessels over time
and is likely to be less susceptible to acute environmental change, but vessels smaller in
diameter than the voxel acquisition size cannot be assessed. On theoretical grounds, one might
expect the two approaches to provide complementary information. Indeed, a recent
comparative study concluded that there was no correlation between vessel tortuosity
measurements and regional cerebral blood flow/volume across tumors of varying histological
type (Parikh 2004).
Much remains unknown about cancer-associated vascular abnormalities. In a thoughtful
review, McDonald notes that it is not only the mechanisms by which the abnormalities are
produced that are poorly understood, but also that it is not yet clear what the implications are
for the rate of cancer growth, predisposition to metastasis, and the delivery of macromolecular
therapeutics to tumor cells (McDonald 2002). As illustrated by the radius changes shown in
Figure 3, the same therapeutic agent may exert differing effects upon different parts of the
vasculature within the same patient. Which parameters (blood flow, blood volume,
permeability, vessel number, vessel tortuosity) are most important when assessing tumor
activity is unknown. Similarly, the time course over which “clinically meaningful vascular
normalization” occurs during treatment is also unknown, and the critical phrase “clinically
meaningful vascular normalization” has yet to be defined.
The fact that the “macro” and “micro” imaging techniques appear to offer complementary
information provides the opportunity to examine a number of important questions. As one
example, Jain has suggested that the abnormal tortuosity of vessels feeding a cancer may reduce
blood flow to a tumor, thus undesirably reducing the delivery of therapeutic agents to the tumor
bed. This hypothesis has led to the potential recommendation of treating cancer by first
delivering an anti-angiogenic agent to normalize the vasculature, thus intentionally
increasing blood flow to the tumor, and then providing direct anti-tumor treatment [Jain
2005]. This hypothesis could be examined directly by using “macro” imaging techniques to
quantify the radius and tortuosity of individual feeding vessels prior to and after anti-angiogenic
treatment while simultaneously examining tumor blood flow and volume using “micro”
imaging techniques. As a second example, abnormal, cancer-associated vessel permeability is
believed to be associated with growth-factor induced changes to the vessel wall [McDonald
2002]. Many different growth factors may be involved, however, and it is unknown whether
Bullitt et al. Page 4













vessel tortuosity changes are induced by the same growth factor(s) that modulate vessel
permeability. If the micro and macro imaging techniques provide different information, it is
possible that the two may provide information about different growth factors and that the
combination of the two imaging modalities could provide more information about tumor
therapeutic response than either could alone. Thirdly, different parts of the same tumor may
respond differently to the same therapy, as may different metastatic lesions within the same
patient. The combination of micro and macro vascular imaging could help explain some of the
current discrepancies in the literature in which perfusion is sometimes reported as increased
and sometimes as decreased following anti-angiogenic therapy [Wildiers 2006, Willett 2004].
More specifically, the combination of micro/macro imaging might also help elucidate which
lesions or portions of a lesion are “responding” or “not responding” to therapy (with the ultimate
definition of what “responding to therapy” really means when correlated with clinical
outcome), and what the importance and potential correlations of the different measures of
vessel shape, vessel perfusion, and vessel permeability are likely to be.
The development of new pharmacological agents that target molecular pathways offers new
hope to cancer patients. An ongoing challenge is the delineation of a method that can determine
both noninvasively and early during a treatment course how effective a therapy will prove to
be. We believe that the study of tumor-associated vascular changes should offer important new
insight into how tumors grow and respond (or fail to respond) to treatment. These same imaging
methods may also provide clinicians an accurate means of non-invasively assessing a tumor’s
malignancy and its response to treatment.
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Healthy (left) and cancer-associated (right) posterior cerebral artery segmented from time-of-
flight, unenhanced brain MRA (MOTSA technique, 5 slabs, TR/TE 35msec/3msec, 0.5 × 0.5
× 0.8 mm3, 352 × 448 × 192 voxels). Note the “many smaller bends upon each larger bend”
that characterize cancer-associated vessel morphology. The closest lesion detectable on
gadolinium-enhanced MR was over a centimeter away.
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Blood flow increase in high grade glioma. A: The patient has a mass in the left parietal lobe
which shows enhancement (arrows) on post contrast T1 weighted image (axial, gadolinium-
enhanced, TR/TE 1700/4.38, voxel size 1 × 1 × 1.5 mm3, voxels 256 × 256 × 130). B: The
corresponding cerebral blood flow map (T2*-weighted EPI sequence, TR/TE 54/2000) shows
a corresponding area of high blood flow (arrows). Red indicates higher blood flow, blue lower.
Interpretation may be complicated by normally high blood flow in grey matter and surface
vessels.
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Improvement of vessel tortuosity abnormalities during successful treatment. A: Axial slice of
a T1-GAD baseline scan showing a large tumor (arrow). Acquisition parameters are the same
as outlined in Figure 2. B: Lateral view of the vessels segmented from the baseline MRA, with
MRA acquisition parameters the same as described in Figure 1. Rectangle outlines the region
magnified in C. C: Tortuosity abnormalities involve both smaller branches and the large
frontopolar arteries (arrows). D: The tumor has regressed at month 2 of treatment (arrow). E:
At month 2 the small, abnormal vessel branches have largely disappeared and there is
normalization of the larger vessels’ shapes. The tumor continued to regress during the following
8 months.
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